1202645-17-7

Basic information

• Product Name: (E)-tert-butyl 3-((diMethylaMino)Methylene)-4-oxopiperidine-1-carboxylate
• Synonyms: (E)-tert-butyl 3-((diMethylaMino)Methylene)-4-oxopiperidine-1-carboxylate;tert-butyl(E)-3-((dimethylamino)methylene)-4-oxopiperidine-1-carboxylate;EOS-60914
• CAS NO: 1202645-17-7
• Molecular Formula: C13H22N2O3
• Molecular Weight: 254.32538
• Mol File: 1202645-17-7.mol
• Article Data: 51

Chemical Properties

• Boiling Point: 357.9±42.0 °C(Predicted)
• Appearance: /
• Density: 1.144±0.06 g/cm3(Predicted)
• PKA: 5.07±0.20(Predicted)
• CAS DataBase Reference: (E)-tert-butyl 3-((diMethylaMino)Methylene)-4-oxopiperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-tert-butyl 3-((diMethylaMino)Methylene)-4-oxopiperidine-1-carboxylate(1202645-17-7)
• EPA Substance Registry System: (E)-tert-butyl 3-((diMethylaMino)Methylene)-4-oxopiperidine-1-carboxylate(1202645-17-7)

Safety Data

• Hazardous Substances Data: 1202645-17-7(Hazardous Substances Data)

Usage

General Description

(E)-tert-butyl 3-((diMethylaMino)Methylene)-4-oxopiperidine-1-carboxylate is a chemical compound with the molecular formula C13H24N2O3. It is a piperidine derivative with a tert-butyl group and a methylamino group attached to the carbon backbone. (E)-tert-butyl 3-((diMethylaMino)Methylene)-4-oxopiperidine-1-carboxylate is often used in organic synthesis as a reagent or intermediate in the production of pharmaceuticals and agrochemicals. It is a yellowish liquid with a slightly fruity odor and is soluble in organic solvents such as ether and chloroform. It should be handled with care due to its potential for causing skin and eye irritation, and it should only be used in a well-ventilated area with appropriate personal protective equipment.

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 5815-08-7 tert-Butoxybis(dimethylamino)methane 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 68-12-2 N,N-dimethyl-formamide 
• 127-19-5 N,N-dimethyl acetamide 
• 1188-33-6 N,N-dimethylformamide diethyl diacetal 

Downstream Products

• 192869-49-1 tert-butyl-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-carboxylate 
• 230301-11-8 1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester 
• 100501-57-3 tert-butyl 2-methyl-6,7-dihydro-2H-pyrazolo(4,3-c)pyridine-5(4H)-carboxylate 
• 1430216-78-6 (E)-4-(5-(3-(5-chloro-2-(1H-tetrazol-1-yl)phenyl)acryloyl)-2-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-4-carboxamido)benzoic acid 
• 869198-95-8 2-amino-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-carboxylic acid tert-butyl ester 

Relevant articles and documents

A knowledge-based, structural-aided discovery of a novel class of 2-phenylimidazo[1,2-a]pyridine-6-carboxamide H-PGDS inhibitors

Through an internal virtual screen at GlaxoSmithKline a distinct class of 2-phenylimidazo[1,2-a]pyridine-6-carboxamide H-PGDS inhibitors were discovered. Careful evaluation of crystal structures and SAR led to a novel, potent, and orally active imidazopyridine inhibitor of H-PGDS, 20b. Herein, describes the identification of 2 classes of inhibitors, their syntheses, and their challenges.

METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS

The present disclosure relates to compositions and methods for the treatment of diseases or disorders (e.g., cancer) with bi-steric inhibitors of mTOR in combination with RAS inhibitors. Specifically, in some embodiments this disclosure includes compositions and methods for inducing apoptosis of tumor cells and/or for delaying, preventing, or treating acquired resistance to RAS inhibitors using bi-steric mTOR inhibitors.

Discovery of IDO1 inhibitors containing a decahydroquinoline, decahydro-1,6-naphthyridine, or octahydro-1H-pyrrolo[3,2-c]pyridine scaffold

A series of IDO1 inhibitors containing a decahydroquinoline, decahydro-1,6-naphthyridine, or octahydro-1H-pyrrolo[3,2-c]pyridine scaffold were identified with good cellular and human whole blood activity against IDO1. These inhibitors contain multiple chiral centers and all diastereomers were separated. The absolute stereochemistry of each isomers were not determined. Compounds 15 and 27 stood out as leads due to their good cellular as well as human whole blood IDO1 inhibition activity, low unbound clearance, and reasonable mean residence time in rat cassette PK studies.